HER2 Positive Gastric Cancer Recruiting Phase 2 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0076824 (HER2 Positive Gastric Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03409848Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric AdenocarcinomaTreatment